Shenyang Xingqi Pharmaceutical Co., Ltd. is a National High-tech Enterprise specializing in the R&D, production and sale of ophthalmic medications. Xinqgi became listed on the ChiNext of Shenzhen Stock Exchange (Stock Name/Abbreviation: XQYY ; Stock Code: 300573) on December 8, 2016. Xingqi was honored with the Silver Medal of the 9th Liaoning Province Governor’s Award in 2022 and was awarded the 20th China Quality Award in 2023.Led by superior Party building, Xingqi pursues high-quality development. Driven by the vision of “growing into a globally competitive ophthalmic medication researcher and manufacturer,” Xingqi has been committed to the mission of promoting health and improving vision and has been truly honoring its company values- perseverance, innovation, responsibility, and win-win benefit-in service for the eye care industry. At present, Xingqi provides a diverse range of high-quality medications across more than ten categories in ophthalmology, including medications slowing the progression of myopia in children, dry eye treatment medications, anti-infectives, anti-infective/anti-inflammatory agents, artificial tears and eye lubricants, nutrition and corneal repair medications, mydriatics and cycloplegia drugs, non-steroidal anti-inflammatory drugs, miotics and anti-glaucoma drugs and intraoperative intraocular irrigation fluids, etc.
Innovation is the driving force for Xingqi Pharmaceutical to grow from strength to strength. Xingqi operates the National Center for Enterprise Technology , National Postdoctoral Research Station, Liaoning Provincial Enterprise Technology Center, Professional Ophthalmological Technology Innovation Center of Liaoning Province, and Myopia Prevention and Control Engineering Research Center for Children and Adolescents of Liaoning Province. In the field of R&D for ophthalmic drugs, Xingqi has established professional ophthalmic pharmaceutical research and evaluation platforms for conventional preparations, in-situ gels, sustained-release preparations, compatibility of pharmaceutical packaging materials, pharmacodynamics, pharmacokinetics, toxicology, etc. In October 2020, CNAS accredited the Quality Inspection Center of Xingqi in acknowledgement of its expertise in undertaking experiments and tests in accordance with recognized standards.
Quality by Design and constant pursuit of elaboration. The Qipan Mountain Factory of Xingqi was fully operated in 2014. It was designed in accordance with the standards of US FDA cGMP and EU GMP and was constructed through collaboration with the world-class design team, equipment suppliers and construction companies. It has multiple production lines that are up to China’s GMP standards, for the manufacture of extract, single dose eye drops, multi-dose eye drops and eye gel.
Xingqi Pharmaceutical focuses on the R&D and production of ophthalmic medications, takes a market-oriented approach and close collaboration with Chinese and international research institutions, medical institutes and ophthalmology experts to accelerate the transformation of scientific research achievements. Through academic promotion, Xingqi has optimized marketing. With a refined marketing system, Xingqi has established partnerships with distributors at various levels, enabling its product sales network into medical institutions at provincial, municipal and county levels nationwide.
Changes and improvements never end at Xingqi Pharmaceutical. Xingqi strives to create long-term values for customers, employees, shareholders, partners and the society, and shoulders the mission of promoting Chinese national medicine based on continuous self-improvement. Xingqier will continue to steadfastly forge ahead to achieve the vision of “growing into a globally competitive ophthalmic medication researcher and manufacturer.”